Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
1(50.0%)
Phase 3
1(50.0%)
2Total
Early Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06129084Active Not Recruiting

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

Role: collaborator

NCT04574960Phase 3Recruiting

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

Role: collaborator

NCT03266900Early Phase 1Terminated

A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival

Role: collaborator

All 3 trials loaded